Tags

Type your tag names separated by a space and hit enter

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study.
Clin Neuropharmacol. 2014 Mar-Apr; 37(2):41-4.CN

Abstract

OBJECTIVE

The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess the clinical effect of cannabis on motor and non-motor symptoms of PD.

METHODS

Twenty-two patients with PD attending the motor disorder clinic of a tertiary medical center in 2011 to 2012 were evaluated at baseline and 30 minutes after smoking cannabis using the following battery: Unified Parkinson Disease Rating Scale, visual analog scale, present pain intensity scale, Short-Form McGill Pain Questionnaire, as well as Medical Cannabis Survey National Drug and Alcohol Research Center Questionnaire.

RESULTS

Mean (SD) total score on the motor Unified Parkinson Disease Rating Scale score improved significantly from 33.1 (13.8) at baseline to 23.2 (10.5) after cannabis consumption (t = 5.9; P < 0.001). Analysis of specific motor symptoms revealed significant improvement after treatment in tremor (P < 0.001), rigidity (P = 0.004), and bradykinesia (P < 0.001).

CONCLUSIONS

There was also significant improvement of sleep and pain scores. No significant adverse effects of the drug were observed. The study suggests that cannabis might have a place in the therapeutic armamentarium of PD. Larger, controlled studies are needed to verify the results.

Authors+Show Affiliations

Department of Neurology, Rabin Medical Center, Beilinson Hospital, Petach Tikva; and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Observational Study

Language

eng

PubMed ID

24614667

Citation

Lotan, Itay, et al. "Cannabis (medical Marijuana) Treatment for Motor and Non-motor Symptoms of Parkinson Disease: an Open-label Observational Study." Clinical Neuropharmacology, vol. 37, no. 2, 2014, pp. 41-4.
Lotan I, Treves TA, Roditi Y, et al. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol. 2014;37(2):41-4.
Lotan, I., Treves, T. A., Roditi, Y., & Djaldetti, R. (2014). Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clinical Neuropharmacology, 37(2), 41-4. https://doi.org/10.1097/WNF.0000000000000016
Lotan I, et al. Cannabis (medical Marijuana) Treatment for Motor and Non-motor Symptoms of Parkinson Disease: an Open-label Observational Study. Clin Neuropharmacol. 2014;37(2):41-4. PubMed PMID: 24614667.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. AU - Lotan,Itay, AU - Treves,Therese A, AU - Roditi,Yaniv, AU - Djaldetti,Ruth, PY - 2014/3/12/entrez PY - 2014/3/13/pubmed PY - 2015/2/5/medline SP - 41 EP - 4 JF - Clinical neuropharmacology JO - Clin Neuropharmacol VL - 37 IS - 2 N2 - OBJECTIVE: The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess the clinical effect of cannabis on motor and non-motor symptoms of PD. METHODS: Twenty-two patients with PD attending the motor disorder clinic of a tertiary medical center in 2011 to 2012 were evaluated at baseline and 30 minutes after smoking cannabis using the following battery: Unified Parkinson Disease Rating Scale, visual analog scale, present pain intensity scale, Short-Form McGill Pain Questionnaire, as well as Medical Cannabis Survey National Drug and Alcohol Research Center Questionnaire. RESULTS: Mean (SD) total score on the motor Unified Parkinson Disease Rating Scale score improved significantly from 33.1 (13.8) at baseline to 23.2 (10.5) after cannabis consumption (t = 5.9; P < 0.001). Analysis of specific motor symptoms revealed significant improvement after treatment in tremor (P < 0.001), rigidity (P = 0.004), and bradykinesia (P < 0.001). CONCLUSIONS: There was also significant improvement of sleep and pain scores. No significant adverse effects of the drug were observed. The study suggests that cannabis might have a place in the therapeutic armamentarium of PD. Larger, controlled studies are needed to verify the results. SN - 1537-162X UR - https://www.unboundmedicine.com/medline/citation/24614667/Cannabis_(medical_marijuana)_treatment_for_motor_and_non-motor_symptoms_of_Parkinson_disease:_an_open-label_observational_study L2 - http://dx.doi.org/10.1097/WNF.0000000000000016 DB - PRIME DP - Unbound Medicine ER -